Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin), will be launched on June 8.

Lyrica Capsules are co-promoted in Japan by Pfizer and Eisai, with both companies working to provide information on its proper use. Likewise, Lyrica OD Tablets will also be co-promoted by both companies in Japan.

Lyrica is indicated for use in patients with neuropathic pain and pain associated with fibromyalgia. Many of these patients are elderly, and there are cases of patients having difficulty swallowing. Lyrica OD Tablets dissolve swiftly inside the mouth, making it an easy form for these patients to take, and are expected to lead to increased convenience when taking medicine.

Through Lyrica, Pfizer and Eisai will continue to contribute to improvement of quality of life in patients suffering from neuropathic pain and pain associated with fibromyalgia.

http://www.acnnewswire.com/topimg/Low_EisaiLyrica.jpg

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Source: Eisai

Contact:

Corporate Communications
Pfizer Japan Inc.
Telephone: +81-3-5309-6644

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120




Copyright 2017 JCN Newswire . All rights reserved.